NASDAQ:JSPR Jasper Therapeutics (JSPR) Stock Price, News & Analysis $14.75 -1.62 (-9.90%) Closing price 04:00 PM EasternExtended Trading$14.76 +0.01 (+0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Jasper Therapeutics Stock (NASDAQ:JSPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$14.09▼$15.8750-Day Range$14.08▼$21.2852-Week Range$9.45▼$72.60Volume47,189 shsAverage Volume19,381 shsMarket Capitalization$16.37 millionP/E RatioN/ADividend YieldN/APrice Target$220.00Consensus RatingHold Company Overview Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing therapies that target c-Kit (CD117), a protein found on hematopoietic stem cells and mast cells. The company is pursuing treatments intended to address diseases involving abnormal immune or blood-cell activity, as well as approaches that may improve preparation for hematopoietic stem-cell transplantation. Jasper’s lead investigational product is briquilimab, formerly known as JSP191. Briquilimab is an anti-CD117 monoclonal antibody designed to deplete certain stem cells and mast cells. The company has studied the therapy in transplantation-related settings, including conditioning regimens for patients with blood disorders, and in mast-cell-driven diseases such as chronic spontaneous urticaria. Briquilimab remains an investigational product and has not been approved for commercial use. Jasper Therapeutics was established in 2018 and became a publicly traded company in 2020 through a business combination. The company is headquartered in Redwood City, California, and conducts its clinical development activities through research and clinical collaborations in the United States and other relevant markets. Jasper has been led by Ronald Martell, an executive with experience in the biotechnology and pharmaceutical industries.AI Generated. May Contain Errors. Read More Jasper Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreJSPR MarketRank™: 1.86819830713 of 5 starsJasper Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 679th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingJasper Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialJasper Therapeutics has a consensus price target of $220.00, representing about 1,391.5% upside from its current price of $14.75.Amount of Analyst CoverageJasper Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Jasper Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Jasper Therapeutics are expected to grow in the coming year, from ($28.23) to ($15.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jasper Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jasper Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJasper Therapeutics has a P/B Ratio of 98.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted645.30% of the float of Jasper Therapeutics has been sold short.Short Interest Ratio / Days to CoverJasper Therapeutics has a short interest ratio ("days to cover") of 16.99, which indicates bearish sentiment.Change versus previous monthShort interest in Jasper Therapeutics has recently increased by 6.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJasper Therapeutics does not currently pay a dividend.Dividend GrowthJasper Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.18 News SentimentJasper Therapeutics has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Jasper Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of Jasper Therapeutics is held by insiders.Percentage Held by Institutions79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jasper Therapeutics' insider trading history. Receive JSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPR Stock News HeadlinesJasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its WarrantsNovember 9 at 8:00 AM | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Shares Gap Down - Time to Sell?November 8 at 4:01 AM | americanbankingnews.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Jasper Therapeutics (JSPR) Projected to Announce Earnings on MondayNovember 8 at 2:40 AM | americanbankingnews.comJasper Therapeutics, Inc. (JSPR) - What Are Analysts Saying About This Stock?November 7 at 4:26 AM | americanbankingnews.comJasper Therapeutics Announces 1-for-30 Reverse Stock SplitNovember 4, 2026 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Stock Rating Upgraded by Wall Street ZenOctober 31, 2026 | americanbankingnews.comJasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA NephropathyOctober 15, 2026 | globenewswire.comSee More Headlines JSPR Stock Analysis - Frequently Asked Questions How have JSPR shares performed this year? Jasper Therapeutics' stock was trading at $54.90 at the beginning of the year. Since then, JSPR shares have decreased by 73.1% and is now trading at $14.75. How were Jasper Therapeutics' earnings last quarter? Jasper Therapeutics, Inc. (NASDAQ:JSPR) announced its quarterly earnings data on Friday, August, 14th. The company reported ($3.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($8.03) by $5.03. When did Jasper Therapeutics' stock split? Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Jasper Therapeutics? Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jasper Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Micron Technology (MU), Definium Therapeutics (DFTX) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 4 days ago, JSPR's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JSPR CIK1788028 Webjaspertherapeutics.com Phone650-549-1400FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Price Target for Jasper Therapeutics$220.00 High Price Target$510.00 Low Price Target$60.00 Potential Upside/Downside+1,391.5%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($47.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.80 million Net MarginsN/A Pretax MarginN/A Return on Equity-884.17% Return on Assets-143.83% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.45 per share Price / Book3.31Miscellaneous Outstanding Shares1,110,000Free Float1,065,000Market Cap$16.37 million OptionableOptionable Beta3.30 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:JSPR) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredIt’s now or neverAnthropic's Claude now generates more revenue than ChatGPT, and the company is about to go public at a $1.5 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
